Affiliation:
1. Hebei Medical University Third Affiliated Hospital
2. The Fourth Affiliated Hospital of Hebei Medical University
Abstract
Abstract
Background
Recent clinical trials have illustrated the superior efficacy and safety of sintilimab plus chemotherapy compared to chemotherapy alone in patients with advanced oesophageal squamous cell carcinoma.
Aim
This study aimed to evaluate the cost-effectiveness of sintilimab combined with chemotherapy vs. Chemotherapy alone as first-line treatment for advanced oesophageal squamous cell carcinoma patients in China.
Method
A partitioned survival model was developed to compare the lifetime costs and quality-adjusted life years of different treatment regimens. Sensitivity analysis was conducted to verify the robustness of the model results.
Results
Compared with chemotherapy alone, the sintilimab combination strategy resulted in an additional 0.58 quality-adjusted life years. The incremental cost-effectiveness ratio was $14,967.31/quality-adjusted life years, lowering the willingness-to-pay threshold ($37,663.26). Subgroup analysis demonstrated that sintilimab + chemotherapy was more cost-effective for patients with PD-L1 CPS ≥ 10. Sensitivity analysis confirmed the base-case analysis results.
Conclusion
The sintilimab combination strategy is a cost-effective option for first-line treatment of advanced oesophageal squamous cell carcinoma patients in China.
Publisher
Research Square Platform LLC